{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T03:14:26Z","timestamp":1781579666371,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shizuoka Prefectural Hospital Organization Medical Research Promotion Project"},{"name":"University of Yamanashi Publication Support Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-45248-z","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T19:25:26Z","timestamp":1773948326000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A prospective study on the predictive value of the modified Glasgow prognostic score in non-small cell lung cancer treated with radiation therapy"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6937-8042","authenticated-orcid":false,"given":"Zhe","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2240-2655","authenticated-orcid":false,"given":"Kengo","family":"Kuriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiko","family":"Oguri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Mutou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1729-3908","authenticated-orcid":false,"given":"Koji","family":"Mitsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2694-1829","authenticated-orcid":false,"given":"Masaki","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Akita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juria","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5230-2041","authenticated-orcid":false,"given":"Kan","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1123-4585","authenticated-orcid":false,"given":"Takafumi","family":"Komiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3512-1166","authenticated-orcid":false,"given":"Hiroshi","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"45248_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"Cancer J. Clin."},{"key":"45248_CR2","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. (2024). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf"},{"issue":"Suppl 2","key":"45248_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/resp.13870","volume":"25","author":"SK Vinod","year":"2020","unstructured":"Vinod, S. K. & Hau, E. Radiotherapy treatment for lung cancer: Current status and future directions. Respirology 25 (Suppl 2), 61\u201371 (2020).","journal-title":"Respirology"},{"key":"45248_CR4","doi-asserted-by":"publisher","first-page":"504","DOI":"10.6004\/jnccn.2017.0050","volume":"15","author":"DS Ettinger","year":"2017","unstructured":"Ettinger, D. S. et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc Netw. 15, 504\u2013535 (2017).","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"45248_CR5","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/cncr.31196","volume":"124","author":"DJ Tandberg","year":"2018","unstructured":"Tandberg, D. J., Tong, B. C., Ackerson, B. G. & Kelsey, C. R. Surgery versus stereotactic body radiation therapy for stage I non\u2013small cell lung cancer: A comprehensive review. Cancer 124, 667\u2013678 (2018).","journal-title":"Cancer"},{"key":"45248_CR6","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.ijrobp.2018.11.051","volume":"103","author":"GM Videtic","year":"2019","unstructured":"Videtic, G. M. et al. Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer. Int. J. Radiat. Oncol. Biol. Phys. 103, 1077\u20131084 (2019).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"45248_CR7","doi-asserted-by":"publisher","first-page":"30076","DOI":"10.1038\/s41598-024-73177-2","volume":"14","author":"L Wang","year":"2024","unstructured":"Wang, L. et al. Long-term survival and failure patterns in inoperable early-stage non-small cell lung cancer following stereotactic body radiotherapy: a single-institution retrospective study. Sci. Rep. 14, 30076 (2024).","journal-title":"Sci. Rep."},{"key":"45248_CR8","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia, S. J. et al. Durvalumab after Chemoradiotherapy in Stage III Non\u2013Small-Cell Lung Cancer. N. Engl. J. Med. 377, 1919\u20131929 (2017).","journal-title":"N. Engl. J. Med."},{"key":"45248_CR9","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia, S. J. et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N. Engl. J. Med. 379, 2342\u20132350 (2018).","journal-title":"N. Engl. J. Med."},{"key":"45248_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01308","author":"DR Spigel","year":"2022","unstructured":"Spigel, D. R. et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non\u2013Small-Cell Lung Cancer. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.21.01308 (2022).","journal-title":"J. Clin. Oncol."},{"key":"45248_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-020-00940-z","volume":"13","author":"Y Chen","year":"2020","unstructured":"Chen, Y., Gao, M., Huang, Z., Yu, J. & Meng, X. SBRT combined with PD-1\/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. J. Hematol. Oncol. 13, 105 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"45248_CR12","first-page":"534","volume":"40","author":"Y Min","year":"2024","unstructured":"Min, Y., Li, X., Chen, H., Xu, Y. & Lan, G. Predicting outcomes of Lung Cancer using the modified glasgow prognostic score: A systematic review and meta-analysis. Pak J. Med. Sci. 40, 534\u2013543 (2024).","journal-title":"Pak J. Med. Sci."},{"key":"45248_CR13","doi-asserted-by":"publisher","first-page":"107505","DOI":"10.1016\/j.lungcan.2024.107505","volume":"189","author":"J Saal","year":"2024","unstructured":"Saal, J. et al. Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition. Lung Cancer. 189, 107505 (2024).","journal-title":"Lung Cancer"},{"key":"45248_CR14","doi-asserted-by":"publisher","first-page":"1094973","DOI":"10.3389\/fsurg.2022.1094973","volume":"9","author":"C Yang","year":"2022","unstructured":"Yang, C., Ren, G. & Yang, Q. Prognostic value of preoperative modified Glasgow prognostic score in surgical non-small cell lung cancer: A meta-analysis. Front. Surg. 9, 1094973 (2022).","journal-title":"Front. Surg."},{"key":"45248_CR15","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1186\/s12885-025-13822-9","volume":"25","author":"R Saeed","year":"2025","unstructured":"Saeed, R., McSorley, S., Cascales, A. & McMillan, D. C. The prognostic\/ predictive value of the systematic inflammatory response in patients receiving immunotherapy for non-small cell lung cancer: a systematic review and meta-analysis. BMC Cancer. 25, 994 (2025).","journal-title":"BMC Cancer"},{"key":"45248_CR16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ijrobp.2015.02.018","volume":"92","author":"T Kishi","year":"2015","unstructured":"Kishi, T. et al. Pretreatment Modified Glasgow Prognostic Score Predicts Clinical Outcomes After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer. Int. J. Radiat. Oncol. Biol. Phys. 92, 619\u2013626 (2015).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"45248_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/jrr\/rrab021","volume":"62","author":"Z Chen","year":"2021","unstructured":"Chen, Z. et al. Modified Glasgow Prognostic Score is predictive of prognosis for non-small cell lung cancer patients treated with stereotactic body radiation therapy: a retrospective study. J. Radiat. Res. 62, 457\u2013464 (2021).","journal-title":"J. Radiat. Res."},{"key":"45248_CR18","unstructured":"Therneau, T. M. A Package for Survival Analysis in R. (2024)."},{"key":"45248_CR19","unstructured":"Kassambara, A., Kosinski, M. & Biecek, P. Survminer: Drawing Survival Curves Using \u2018Ggplot2\u2019. (2021)."},{"key":"45248_CR20","doi-asserted-by":"publisher","unstructured":"Gordon, M. & Lumley, T. Forestplot: Advanced Forest Plot Using \u2018grid\u2019 Graphics. (2024). https:\/\/doi.org\/10.32614\/CRAN.package.forestplot","DOI":"10.32614\/CRAN.package.forestplot"},{"key":"45248_CR21","doi-asserted-by":"publisher","first-page":"e0184412","DOI":"10.1371\/journal.pone.0184412","volume":"12","author":"J Jin","year":"2017","unstructured":"Jin, J., Hu, K., Zhou, Y. & Li, W. Clinical utility of the modified Glasgow prognostic score in lung cancer: A meta-analysis. PLoS ONE. 12, e0184412 (2017).","journal-title":"PLoS ONE"},{"key":"45248_CR22","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.12659\/MSM.903710","volume":"23","author":"Y Lv","year":"2017","unstructured":"Lv, Y. et al. Modified Glasgow Prognostic Score at Recurrence Predicts Poor Survival in Resected Non-Small Cell Lung Cancer (NSCLC) Patients. Med. Sci. Monit. 23, 3780\u20133788 (2017).","journal-title":"Med. Sci. Monit."},{"key":"45248_CR23","doi-asserted-by":"publisher","first-page":"e35962","DOI":"10.1097\/MD.0000000000035962","volume":"102","author":"Y Xie","year":"2023","unstructured":"Xie, Y., Li, H. & Hu, Y. Prognostic value of pretreatment modified Glasgow Prognostic Score in small cell lung cancer: A meta-analysis. Med. (Baltim). 102, e35962 (2023).","journal-title":"Med. (Baltim)."},{"key":"45248_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2020.03.024","author":"D Patil","year":"2020","unstructured":"Patil, D. et al. Dynamic Evaluation of the Modified Glasgow Prognostic Scale in Patients with Resected, Localized Clear Cell Renal Cell Carcinoma. Urology https:\/\/doi.org\/10.1016\/j.urology.2020.03.024 (2020). doi:10.1016\/j.urology.2020.03.024.","journal-title":"Urology"},{"key":"45248_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.5301\/ijbm.5000308","volume":"33","author":"J Jin","year":"2018","unstructured":"Jin, J., Hu, K., Zhou, Y. & Li, W. Prognostic value of the Glasgow prognostic score in lung cancer: evidence from 10 studies. Int. J. Biol. Markers. 33, 201\u2013207 (2018).","journal-title":"Int. J. Biol. Markers"},{"key":"45248_CR26","doi-asserted-by":"publisher","first-page":"1449853","DOI":"10.3389\/fonc.2024.1449853","volume":"14","author":"J Wu","year":"2024","unstructured":"Wu, J., Wang, H., Yang, R., Liu, D. & Li, W. Prognostic significance of the modified Glasgow Prognostic Score in NSCLC patients undergoing immune checkpoint inhibitor therapy: a meta-analysis. Front. Oncol. 14, 1449853 (2024).","journal-title":"Front. Oncol."},{"key":"45248_CR27","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/sj.bjc.6606087","volume":"104","author":"MJ Proctor","year":"2011","unstructured":"Proctor, M. J. et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br. J. Cancer. 104, 726\u2013734 (2011).","journal-title":"Br. J. Cancer"},{"key":"45248_CR28","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/ajco.13055","volume":"14","author":"XF Ni","year":"2018","unstructured":"Ni, X. F. et al. Effect of C-reactive protein\/albumin ratio on prognosis in advanced non-small-cell lung cancer. Asia Pac. J. Clin. Oncol. 14, 402\u2013409 (2018).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"45248_CR29","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.lungcan.2015.03.020","volume":"88","author":"CP Simmons","year":"2015","unstructured":"Simmons, C. P. et al. Prognosis in advanced lung cancer\u2013A prospective study examining key clinicopathological factors. Lung Cancer. 88, 304\u2013309 (2015).","journal-title":"Lung Cancer"},{"key":"45248_CR30","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s00595-016-1448-8","volume":"47","author":"T Miyazaki","year":"2017","unstructured":"Miyazaki, T. et al. Ratio of C-reactive protein to albumin is a prognostic factor for operable non-small-cell lung cancer in elderly patients. Surg. Today. 47, 836\u2013843 (2017).","journal-title":"Surg. Today"},{"key":"45248_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.lungcan.2020.11.026","volume":"152","author":"S Takamori","year":"2021","unstructured":"Takamori, S. et al. Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer. 152, 27\u201333 (2021).","journal-title":"Lung Cancer"},{"key":"45248_CR32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.resinv.2022.10.003","volume":"61","author":"T Tanaka","year":"2023","unstructured":"Tanaka, T. et al. Prognostic role of modified Glasgow Prognostic score in elderly non-small cell lung cancer patients treated with anti-PD-1 antibodies. Respiratory Invest. 61, 74\u201381 (2023).","journal-title":"Respiratory Invest."},{"key":"45248_CR33","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","volume":"402","author":"JY Chang","year":"2023","unstructured":"Chang, J. Y. et al. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet 402, 871\u2013881 (2023).","journal-title":"Lancet"},{"key":"45248_CR34","doi-asserted-by":"crossref","unstructured":"Pircher, A. et al. 117O Stereotactic body radiotherapy (SBRT) with pembrolizumab (pembro) for unresected stage I\/II non-small cell lung cancer (NSCLC): The randomized, double-blind, phase III KEYNOTE-867 study. Immuno-Oncology Technology 24, 100746 (2024).","DOI":"10.1016\/j.iotech.2024.100746"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45248-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45248-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45248-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:29:08Z","timestamp":1777937348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45248-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["45248"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-45248-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14242"}}